Actively Recruiting
Phase I Study to Assess Safety and Effects of Single and Multiple Doses of ICP-538 Tablets in Healthy Adults Aged 18 to 50
Led by Beijing InnoCare Pharma Tech Co., Ltd. · Updated on 2026-06-18
104
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ICP-538 in healthy adult participants. The study aims to understand how the drug behaves in the body and monitor any adverse effects in a controlled setting. This trial is sponsored by Beijing InnoCare Pharma Tech Co., Ltd. and focuses on healthy individuals aged 18 to 50 years. Participants will receive either single ascending doses or multiple ascending doses of ICP-538 tablets or matching placebo tablets. The study uses a parallel design with randomized allocation and quadruple masking to ensure unbiased results. Dosing and monitoring will occur over a period that can last up to 7 weeks, during which the drugs effects and behavior in the body will be closely observed. During the study, participants will undergo regular assessments including vital signs, physical examinations, laboratory tests, ECGs, chest X-rays, and abdominal ultrasounds to track safety and drug effects. Researchers will measure treatment-emergent adverse events, abnormalities in laboratory tests, and vital signs throughout the study period. Participant involvement includes signing informed consent, adhering to study protocols, and attending scheduled visits for evaluations and monitoring until study completion.
CONDITIONS
Brief Title
Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy Subjects
Research Team
Q
Quankun Zhuang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here